Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare – a retrospective, phase IV, non-interventional study

References

• Sun P, Ma L, Diao G, et al. Application of indirect linkage analysis and direct genotyping to hemophilia. A carrier detection in Sichuan, China. Genet Mol Res 2015;14:8229-35
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Guidelines for the Management of Hemophilia, 2nd edition. 2012. Available at: http://www1.wfh.org/publication/files/pdf-1472.pdf [Last accessed 18 December 2015]
   Google Scholar
• World Federation of Hemophilia. Report on the Annual Global Survey 2014. October 2015. Available at: http://www1.wfh.org/publications/files/pdf-1627.pdf [Last accessed 22 February 2016]
   Google Scholar
• Yanji Q, Xiaolu N, Zhirong,Y, et al. Meta-analysis of the prevalence of hemophilia in mainland China. Chin J Hematol 2014;35:65-8
   Google Scholar
• Rossbach HC. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. Vasc Health Risk Manag 2010;6:59-68
   PubMedGoogle Scholar
• Ranta S, Viljakainen H, Mäkipernaa A, et al. Hypercalciuria in children with haemophilia suggests primary skeletal pathology. Br J Hematol 2011;153:364-71
   PubMed Web of Science ®Google Scholar
• Wells AJ, McLaughlin P, Simmonds JV, et al. A case–control study assessing bone mineral density in severe haemophilia A in the UK. Haemophilia 2015;21:109-15
   PubMed Web of Science ®Google Scholar
• Xue F, Sun C, Sui T, et al. Hemophilic pseudotumor in Chinese patients: a retrospective single centered analysis of 14 cases. Clin Appl Thromb Hemost 2011;17:279-82
   PubMed Web of Science ®Google Scholar
• Furlan R, Krishnan S, Vietri J. Patient and parent preferences for characteristics of prophylactic treatment in hemophilia. Patient Prefer Adherence 2015;9:1687-94
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Zimmermann R, Katsarou O, et al. Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. Haemophilia 2015;21:171-9
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. NEJM 2007;357:535-44
   PubMed Web of Science ®Google Scholar
• Tiede A, Oldenburg J, Lissitchkov T, et al. Prophylaxis vs. on demand treatment with Nuwiq (Humancl rhFVIII) in adults with severe haemophilia A. Haemophilia 2016;22:374-80
   PubMed Web of Science ®Google Scholar
• Wu R, Luke KH, Poon MC, et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011;17:70-4
   PubMed Web of Science ®Google Scholar
• Poon MC, Lee A. Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? Thromb J 2016;14(Suppl 1):32
   PubMed Web of Science ®Google Scholar
• Ghosh K, Ghosh K. Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus 2016;32:347-55
   PubMed Web of Science ®Google Scholar
• The World Federation of Hemophilia’s Sixth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders. Available at: http://www1.wfh.org/publications/files/pdf-1274.pdf [Last accessed 21 December 2015]
   Google Scholar
• Ono O, Suzuki Y, Yosikawa K, et al. Assessment of haemophilia treatment practice pattern in Japan. Haemophilia 2009;15:1032-8
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao Y, Sun J, et al. Six-month clinical observation on safety and efficacy of a full-length recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A. Haemophilia 2011;17:538-41
   PubMed Web of Science ®Google Scholar
• Tu TC, Liou WS, Chou TY, et al. Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in Taiwan. Yonsei Med J 2013;54:71-80
   PubMed Web of Science ®Google Scholar
• Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-13
   PubMed Web of Science ®Google Scholar
• O’Mahony B, Noone D, Giangrande PLF, et al. Haemophilia care in Europe – a survey of 35 countries. Haemophilia 2013;19:e239-47
   PubMed Web of Science ®Google Scholar
• Traore AN, Chan AK, Webert KE, et al. First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System. Haemophilia 2014;20:e251-9
   PubMed Web of Science ®Google Scholar
• Linden JV, Kolakoski MH, Lima JE, et al. Factor concentrate usage in persons with hemophilia in New York State. Transfusion 2003;43:470-5
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Brooker M, Amand RE, et al. A study of reported factor VIII use around the world. Haemophilia 2010;16:33-46
   PubMed Web of Science ®Google Scholar
• Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association/Hemophilia Treatment Center Collaborative Network of China. [Consensus of Chinese experts on diagnosis and treatment of hemophilia (2013)]. Zhonghua Xue Ye Xue Za Zhi 2013;34:461-3
   PubMedGoogle Scholar
• Fischer K, Collins PW, Ozelo MC, et al. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost 2016;14:1105-9
   PubMed Web of Science ®Google Scholar
• Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008;14:671-84
   PubMed Web of Science ®Google Scholar
• Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012;10:165-8
   PubMed Web of Science ®Google Scholar
• Berntorp E, Astermark J, Björkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(Suppl 1):1-4
   PubMed Web of Science ®Google Scholar